Related Experiment Video

Updated: Mar 31, 2026

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.5K

Ventricular tachycardia in ischemic cardiomyopathy; a combined endo-epicardial ablation as the first procedure versus

Astrid A Hendriks1,2, Muchtiar Khan3, Laszlo Geller4

  • 1Department of Clinical Electrophysiology, Erasmus Medical Center, Postbus 2040, 3015, CE, Rotterdam, The Netherlands. hendriksastrid@hotmail.com.

Trials
|October 31, 2015
PubMed

Insights

This study investigates if combining endocardial and epicardial ablation for ventricular tachycardia (VT) in ischemic heart disease patients is better than endocardial ablation alone. The goal is to reduce VT recurrence and improve outcomes.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiac Surgery

Background:

  • The role of epicardial ablation for ventricular tachycardia (VT) in ischemic heart disease is not well-defined.
  • Epicardial ablation is standard for nonischemic cardiomyopathies but often a secondary approach in ischemic VT.
  • Previous studies suggest epicardial VT ablation improves outcomes, but often after failed endocardial procedures.

Purpose of the Study:

  • To evaluate if combined endo-epicardial scar homogenization improves outcomes for VT ablation in ischemic heart disease.
  • To compare a first-line combined approach versus endocardial ablation alone.

Main Methods:

  • The EPILOGUE study is a multicenter, randomized controlled trial.
  • Patients with ischemic heart disease undergoing VT ablation are randomized to either combined endo-epicardial or endocardial scar homogenization.
  • The primary outcome is the recurrence of sustained VT over a 2-year follow-up period.

Main Results:

  • This section is not available in the provided abstract.

Conclusions:

  • This is the first randomized trial to assess combined endo-epicardial scar homogenization versus endocardial scar homogenization for ischemic scar-related VT.
  • The study aims to clarify the efficacy of a first-line combined approach in managing VT in this patient population.
Abstract

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
637
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
957
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
615
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
708
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
757